Adalimumab (Humira, AbbVie), an immunosuppressive biologic therapy, improves the symptoms of noninfectious active uveitis, but causes some adverse events and does not cure the disease, researchers say.
The US Food and Drug Administration (FDA) is expediting its review of a new potential treatment for giant cell arteritis, a rare inflammatory disease that can cause permanent vision loss, Roche has announced.
Some laser pointers available for less than €20 exceed the legal limits on their power by as much as 127 fold, according to Australian researchers. They have called on regulators to consider a ban on green laser pointers.
Intas Pharmaceuticals of Ahmedabad, India, seems to have overcome the manufacturing problems that led to ocular inflammation in 10% of the patients injected with the first three batches of razumab, a biosimilar for ranibizumab, according to two ophthalmologists who have administered the drug.